Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Almirall SA
After highlighting oncology drugs pegged to make a splash next year with the help of Biomedtracker, Scrip takes a look at seven potential blockbusters across a range of therapeutic areas including neurology, dermatology and blood disorders slated for approval next year.
The Australian company is steadily growing its photoprotective drug in adults with erythropoietic protoporphyria but also sees a big opportunity in the pigment loss disorder.
Amylyx is funding research at the Sunnybrook Research Institute to investigate Bax and Bak inhibition in neurodegenerative disease. Repertoire looks into HPV+ cancer with Memorial Sloan Kettering.
Opzelura, already approved for atopic dermatitis, gives Incyte a second indication for its topical JAK inhibitor. It is the first treatment approved for vitiligo.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Almirall S.A.
- Almirall LLC
- Aqua Pharmaceuticals
- Taurus Pharma GmbH
- Polichem S.A.
- Polichem S.r.l.